MKC Stock Analysis: McCormick | NYSE
Packaged Foods | NYSE, USA | Market Cap: 12.361m USD | 12M Return: -30% | US5797802064 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 187M
EPS Trend: 91.3%
Qual. Beats: 3
Rev. Trend: 82.7%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
McCormick & Company (NYSE: MKC) is a U.S.-based packaged foods company that manufactures, markets, and distributes spices, herbs, seasoning mixes, condiments, and other flavor products. Founded in 1889 and headquartered in Hunt Valley, Maryland, the company has been publicly traded since 1972 and operates through two business segments: Consumer (retail-facing branded products) and Flavor Solutions (ingredients and flavor systems sold to food manufacturers and foodservice operators). Its Consumer segment sells under a wide portfolio of regional and global brands-including McCormick, Frenchs, Franks RedHot, Lawrys, Cholula, OLD BAY, Ducros, Schwartz, and Kamis-across the Americas, EMEA, and APAC, while also supplying private-label products to grocery, mass merchandise, warehouse clubs, discount, drug, and e-commerce retailers.
McCormicks dual B2C/B2B structure is a notable feature within the packaged foods and meats sub-industry, giving it both branded consumer exposure and a more stable, contract-oriented industrial revenue stream through Flavor Solutions. As a Consumer Staples issuer, the company benefits from relatively inelastic demand for cooking and seasoning products, though it remains subject to input cost volatility from agricultural commodities such as pepper, paprika, and other spices sourced globally.
- Spice demand resilient as at-home cooking trends persist
- Flavor Solutions segment margins pressured by raw material costs
- Cholula and Franks RedHot acquisitions drive premium condiment growth
| Net Income: 1.50b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -0.43 > 1.0 |
| NWC/Revenue: -19.71% < 20% (prev -13.20%; Δ -6.51% < -1%) |
| CFO/TA 0.07 > 3% & CFO 1.14b > Net Income 1.50b |
| Net Debt (4.08b) to EBITDA (1.39b): 2.94 < 3 |
| Current Ratio: 0.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (269.4m) vs 12m ago 0.04% < -2% |
| Gross Margin: 39.06% > 18% (prev 38.22%; Δ 0.85% > 0.5%) |
| Asset Turnover: 51.41% > 50% (prev 51.24%; Δ 0.17% > 0%) |
| Interest Coverage Ratio: 4.96 > 6 (EBIT TTM 1.11b / Interest Expense TTM 224.9m) |
| A: -0.09 (Total Current Assets 2.90b - Total Current Liabilities 4.42b) / Total Assets 16.7b |
| B: 0.29 (Retained Earnings 4.81b / Total Assets 16.7b) |
| C: 0.07 (EBIT TTM 1.11b / Avg Total Assets 14.9b) |
| D: 0.77 (Book Value of Equity 7.00b / Total Liabilities 9.06b) |
| Altman-Z'' = 1.66 = BB |
| DSRI: 1.10 (Receivables 831.5m/668.7m, Revenue 7.69b/6.79b) |
| GMI: 0.98 (GM 38.22% / 39.06%) |
| AQI: 1.01 (AQ_t 0.73 / AQ_t-1 0.72) |
| SGI: 1.13 (Revenue 7.69b / 6.79b) |
| TATA: 0.02 (NI 1.50b - CFO 1.14b) / TA 16.7b) |
| Beneish M = -2.86 (Cap -4..+1) = A |
As of October 12, 2026, the stock is trading at USD 44.81 with a total of 3,364,011 shares traded. Over the past week, the price has changed by +0.31%, over one month by -12.96%, over three months by -13.06% and over the past year by -30.04%.
Current recommended Stop Loss: 42.80 (which is 4.5% or 1.4 ATR below the current price).
McCormick has received a consensus analysts rating of 3.73. Therefore, it is recommended to hold MKC.
- StrongBuy: 4
- Buy: 3
- Hold: 8
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 54.9 | 22.4% |
P/E Trailing = 8.3074
P/E Forward = 14.2653
P/S = 1.6083
P/B = 1.8866
P/EG = 1.9027
Revenue TTM = 7.69b USD
EBIT TTM = 1.11b USD
EBITDA TTM = 1.39b USD
Long Term Debt = 3.11b USD (from longTermDebt, last fiscal year)
Short Term Debt = 1.34b USD (from shortTermDebt, last quarter)
Debt = 4.41b USD (from shortLongTermDebtTotal, last quarter) + Leases 167.7m
Net Debt = 4.08b USD (calculated: Debt 4.41b - CCE 331.1m)
Enterprise Value = 16.4b USD (12.4b + Debt 4.41b - CCE 331.1m)
Interest Coverage Ratio = 4.96 (Ebit TTM 1.11b / Interest Expense TTM 224.9m)
EV/FCF = 17.76x (Enterprise Value 16.4b / FCF TTM 925.9m)
FCF Yield = 5.63% (FCF TTM 925.9m / Enterprise Value 16.4b)
FCF Margin = 12.05% (FCF TTM 925.9m / Revenue TTM 7.69b)
Net Margin = 19.52% (Net Income TTM 1.50b / Revenue TTM 7.69b)
Gross Margin = 39.06% ((Revenue TTM 7.69b - Cost of Revenue TTM 4.68b) / Revenue TTM)
Gross Margin QoQ = 39.26% (prev 40.18%)
Tobins Q-Ratio = 0.99 (Enterprise Value 16.4b / Total Assets 16.7b)
Interest Expense / Debt = 5.10% (Interest Expense 224.9m / Debt 4.41b)
Taxrate = 26.73% (227.7m / 851.9m)
NOPAT = 816.8m (EBIT 1.11b * (1 - 26.73%))
Current Ratio = 0.66 (Total Current Assets 2.90b / Total Current Liabilities 4.42b)
Debt / Equity = 0.63 (Debt 4.41b / totalStockholderEquity, last quarter 7.00b)
Debt / EBITDA = 2.94 (Net Debt 4.08b / EBITDA 1.39b)
Debt / FCF = 4.41 (Net Debt 4.08b / FCF TTM 925.9m)
Total Stockholder Equity = 6.68b (last 4 quarters mean from totalStockholderEquity)
RoA = 10.04% (Net Income 1.50b / Total Assets 16.7b)
RoE = 22.47% (Net Income TTM 1.50b / Total Stockholder Equity 6.68b)
RoCE = 11.39% (EBIT 1.11b / Capital Employed (Equity 6.68b + L.T.Debt 3.11b))
RoIC = 6.17% (NOPAT 816.8m / Invested Capital 13.2b)
WACC = 5.63% (E(12.4b)/V(16.8b) * Re(6.31%) + D(4.41b)/V(16.8b) * Rd(5.10%) * (1-Tc(0.27)))
Discount Rate = 6.31% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -83.87 | Cagr: -0.05%
[DCF] Terminal Value 77.97% ; FCFF base≈872.9m ; Y1≈1.00b ; Y5≈1.47b
[DCF] Fair Price = 71.02 (EV 22.2b - Net Debt 4.08b = Equity 18.1b / Shares 254.5m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 91.30 | EPS CAGR: 5.38% | SUE: 1.73 | # QB: 3
Revenue Correlation: 82.75 | Revenue CAGR: 4.33% | SUE: 1.58 | # QB: 1
EPS current Quarter (2027-02-28): EPS=0.64 | Chg30d=-4.31% | Revisions=-40% | Analysts=4
EPS current Year (2026-11-30): EPS=3.09 | Chg30d=+0.06% | Revisions=+0% | GrowthEPS=+3.0% | GrowthRev=+15.8%
EPS next Year (2027-11-30): EPS=3.21 | Chg30d=-2.54% | Revisions=-40% | GrowthEPS=+4.0% | GrowthRev=+2.9%
[Analyst] Revisions Ratio: -44% (up=1, down=5)